The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.
News|Poll|September 5, 2014
Pruritic Skin Lesions In Various States of Healing
A 56-year-old woman presents with pruritic skin lesions on the arms and legs. What does this pattern suggest?
Advertisement
A 56-year-old woman presents with pruritic skin lesions on the arms and legs.
What does this pattern suggest?
Advertisement
Related to this article
Takeda’s oral TYK2 inhibitor showed rapid skin clearance in phase 3 psoriasis trials as FDA fast-tracks review; decision expected early 2027.
Advertisement
Advertisement
Trending on Patient Care Online
1
GLP-1 RAs for Weight Management: A Primary Care Approach to Risk and Monitoring
2
FDA Expands Baricitinib Approval to Adolescents With Severe Alopecia Areata
3
ACCORD Trials: Efficacy and Safety of Dextromethorphan-Bupropion in Agitation
4
Safety, Dosing, and Drug Interactions for Dextromethorphan-Bupropion in Agitation
5